By measuring the levels of CREB3L1 in tumor biopsies before chemotherapy and using doxorubicin only in patients with cancers expressing CREB3L1, the response rate of doxorubicin may be markedly improved for cancers such as breast cancer that are treated with chemotherapeutic regime containing doxorubicin but with a low response rate [18]. Here, CREB3L1 is linked to breast cancer.